Literature DB >> 3873302

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

S C Ridge, A E Sloboda, R A McReynolds, S Levine, A L Oronsky, S S Kerwar.   

Abstract

Treatment of rats with a developing or an established lesion of experimental allergic encephalomyelitis (EAE) with mitoxantrone (Novantrone) suppressed the hind limb paralysis associated with the disease. Histopathological examination of the spinal cords of these rats showed that mitoxantrone-treated rats had reduced vascular lesions that are associated with EAE. Spleen cells derived from immunized rats that had been treated in vivo with mitoxantrone did not transfer disease when these cells were administered to naive syngenic recipients. In addition, spleen cells from diseased rats did not transfer EAE lesions when these cells were administered to recipients that had been treated with mitoxantrone. Recipients treated with mitoxantrone were resistant to EAE lesions induced by sensitized cells in a rapid passive transfer system. Finally, when spleen cells from rats with EAE were incubated, in vitro, with mitoxantrone, these cells did not transfer disease to recipients. Thus the present studies indicate that treatment with mitoxantrone can suppress the lesions associated with both the active and passive forms of EAE.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873302     DOI: 10.1016/0090-1229(85)90075-3

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  23 in total

Review 1.  Combination therapies in multiple sclerosis.

Authors:  Ralf Gold
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

Review 2.  Mechanisms of immune-mediated demyelinating disease of the central nervous system.

Authors:  D Baker; A N Davison
Journal:  Neurochem Res       Date:  1991-09       Impact factor: 3.996

Review 3.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 4.  Immunosuppressive agents in multiple sclerosis.

Authors:  Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

5.  Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Authors:  G Edan; D Miller; M Clanet; C Confavreux; O Lyon-Caen; C Lubetzki; B Brochet; I Berry; Y Rolland; J C Froment; E Cabanis; M T Iba-Zizen; J M Gandon; H M Lai; I Moseley; O Sabouraud
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

Review 6.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

Review 7.  Mitoxantrone: a review of its use in multiple sclerosis.

Authors:  Lesley J Scott; David P Figgitt
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  [Mitoxanthrone in the therapy of multiple sclerosis].

Authors:  B C Kieseier; R Gold; H-P Hartung
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

9.  Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis.

Authors:  Samuel A Burns; R Lee Archer; Janet A Chavis; Cameron A Tull; Lori L Hensley; Paul D Drew
Journal:  Brain Res       Date:  2012-08-02       Impact factor: 3.252

10.  The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis.

Authors:  F X Weilbach; A Chan; K V Toyka; R Gold
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.